RxDoctor Payments Data

Patricia Seay, PA

Medical · South Lyon, MINPI 1528342078

Payments from drug & device makers

$4,422in general payments, 2019–2025

Across 233 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$720
  • AstraZeneca$707
  • Otsuka America Pharmaceutical, Inc.$484
  • Orexo US, Inc.$425
  • Pfizer$403
  • Exact Sciences$210
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,422 in reported general payments places this provider in the 85th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$12,426
Medicare patients
48
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate33$27,967
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl197$24,301
EliquisApixaban28$21,797
JardianceEmpagliflozin12$19,381
SuboxoneBuprenorphine Hcl/Naloxone Hcl19$9,452
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,809
ZubsolvBuprenorphine Hcl/Naloxone Hcl17$7,658
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,423
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,411
Diclofenac Sodium63$1,935
Albuterol Sulfate HfaAlbuterol Sulfate62$1,634
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen113$1,426
Pregabalin36$1,176
Atorvastatin Calcium98$1,019
Lidocaine36$716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$52$27,96733 claims
PfizerEliquis$403$21,79728 claims
Boehringer IngelheimJardiance$143$19,38112 claims
Indivior Inc.Suboxone$31$9,45219 claims
GSKTrelegy Ellipta$96$7,80912 claims
Orexo US, Inc.Zubsolv$425$7,65817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 755 medical providers in Michigan.

Other medical in South Lyon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →